National Institutes of Health—October 3, 2017
National Institutes of Health reported on a recent study that stated that genetic testing can help predict the best blood thinner dose to give to a patient undergoing joint replacement surgery.
The article reported that there were fewer adverse events in the group with genetically guided doses verses those who received clinically guided doses.
"About half of the population, because of genetic variants, is very sensitive to warfarin or has a very unpredictable or delayed response to the drug. This is the first study to show that adjusting the dose based on these genetic variants makes warfarin safer for patients," said HSS rheumatologist Anne R. Bass, MD, who co-authored the study.
Read the full article at nih.gov